{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:08:27Z","timestamp":1787616507468,"version":"build-2736575974"},"publisher-location":"Singapore","reference-count":120,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811314346","type":"print"},{"value":"9789811314353","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-981-13-1435-3_21","type":"book-chapter","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T07:48:45Z","timestamp":1541144925000},"page":"463-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drugs of Muscle Wasting and Their Therapeutic Targets"],"prefix":"10.1007","author":[{"given":"Kunihiro","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,3]]},"reference":[{"issue":"4","key":"21_CR1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00198-009-1059-y","volume":"21","author":"T Lang","year":"2010","unstructured":"Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB (2010) Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 21(4):543\u2013559","journal-title":"Osteoporos Int"},{"key":"21_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcdb.2015.11.002","volume":"54","author":"M Sandri","year":"2016","unstructured":"Sandri M (2016) Protein breakdown in cancer cachexia. Semin Cell Dev Biol 54:11\u201319","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"21_CR3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/1871530311313010008","volume":"13","author":"M Zamboni","year":"2013","unstructured":"Zamboni M, Rossi AP, Corzato F, Bambace C, Mazzali G, Fantin F (2013) Sarcopenia, cachexia and congestive heart failure in the elderly. Endocr Metab Immune Disord Drug Targets 13(1):58\u201367","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"21_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13539-011-0052-4","volume":"3","author":"K Sakuma","year":"2012","unstructured":"Sakuma K, Yamaguchi A (2012) Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 3(2):77\u201394","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5\u20136","key":"21_CR5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00424-016-1933-3","volume":"469","author":"K Sakuma","year":"2017","unstructured":"Sakuma K, Aoi W, Yamaguchi A (2017) Molecular mechanism of sarcopenia and cachexia: recent research advances. Pflugers Arch 469(5\u20136):573\u2013591","journal-title":"Pflugers Arch"},{"issue":"5","key":"21_CR6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.celrep.2014.07.061","volume":"8","author":"S Carnio","year":"2014","unstructured":"Carnio S, LoVerso F, Baraibar MA, Longa E, Khan MM, Maffei M, Reischl M, Canepari M, Loefler S, Kern H, Blaauw B, Friguet B, Bottinelli R, Rudolf R, Sandri M (2014) Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep 8(5):1509\u20131521","journal-title":"Cell Rep"},{"issue":"2","key":"21_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/jcsm.12045","volume":"7","author":"K Sakuma","year":"2016","unstructured":"Sakuma K, Kinoshita M, Ito Y, Aizawa M, Aoi W, Yamaguchi A (2016) p62\/SQSTM1 but not LC3 is accumulated in sarcopenic muscle of mice. J Cachexia Sarcopenia Muscle 7(2):204\u2013212","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"21_CR8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.exger.2009.11.002","volume":"45","author":"SE Wohlgemuth","year":"2010","unstructured":"Wohlgemuth SE, Seo AY, Marzetti E, Lees HA, Leeuwenburgh C (2010) Skeletal muscle autophagy and apoptosis during aging: effects of calorie restriction and life-long exercise. Exp Gerontol 45(2):138\u2013148","journal-title":"Exp Gerontol"},{"issue":"2","key":"21_CR9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1874609811003020090","volume":"3","author":"K Sakuma","year":"2010","unstructured":"Sakuma K, Yamaguchi A (2010) Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr Aging Sci 3(2):90\u2013101","journal-title":"Curr Aging Sci"},{"issue":"2","key":"21_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1574884708666131111192845","volume":"9","author":"H Wakabayashi","year":"2013","unstructured":"Wakabayashi H, Sakuma K (2013) Comprehensive approach to sarcopenia treatment. Curr Clin Pharmacol 9(2):171\u2013180","journal-title":"Curr Clin Pharmacol"},{"issue":"12","key":"21_CR11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, Hochberg MC, Ferrari SL, Blain H, Binder EF, Rolland Y, Poiraudeau S, Benson CT, Myers SL, Hu L, Ahmad QI, Pacuch KR, Gomez EV, Benichou O, STEADY Group (2015) Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol 3(12):948\u2013957","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"21_CR12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/21678707.2016.1240613","volume":"4","author":"JM Spinazzola","year":"2016","unstructured":"Spinazzola JM, Kunkel LM (2016) Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy. Expert Opin Orphan Drugs 4(11):1179\u20131194","journal-title":"Expert Opin Orphan Drugs"},{"issue":"4","key":"21_CR13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomized, double-blind, phase 3 trials. Lancet Oncol 17(4):519\u2013531","journal-title":"Lancet Oncol"},{"issue":"10","key":"21_CR14","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.biocel.2013.05.035","volume":"45","author":"T Yoshida","year":"2013","unstructured":"Yoshida T, Tabony AM, Galvez S (2013) Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol 45(10):2322\u20132332","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"21_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00394-017-1593-x","volume":"15","author":"S Tabata","year":"2018","unstructured":"Tabata S, Aizawa M, Kinoshita M, Ito Y, Kawamura Y, Takebe M, Pan W, Sakuma K (2018) The influence of isoflavone for denervation-induced muscle atrophy. Eur J Nutr 15(6):628\u2013637. https:\/\/doi.org\/10.1007\/s00394-017-1593-x","journal-title":"Eur J Nutr"},{"issue":"2","key":"21_CR16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jcsm.12162","volume":"8","author":"R Yu","year":"2017","unstructured":"Yu R, Chen JA, Xu J, Cao J, Wang Y, Thomas SS, Hu Z (2017) Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease. J Cachexia Sarcopenia Muscle 8(2):327\u2013341","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"21_CR17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nm.4363","volume":"23","author":"B Benoit","year":"2017","unstructured":"Benoit B, Meugnier E, Castelli M, Chanon S, Vieille-Marchiset A, Durand C, Bendridi N, Pesenti S, Monternier PA, Durieux AC, Freyssenet D, Rieusset J, Lefai E, Vidal H, Ruzzin J (2017) Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat Med 23(8):990\u2013996","journal-title":"Nat Med"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.cellbio.20.012103.135836","volume":"20","author":"SJ Lee","year":"2004","unstructured":"Lee SJ (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61\u201386","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"2","key":"21_CR19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00424-014-1527-x","volume":"467","author":"K Sakuma","year":"2015","unstructured":"Sakuma K, Aoi W, Yamaguchi A (2015) Current understanding of sarcopenia: possible candidates modulating muscle mass. Pflugers Arch 467(2):213\u2013229","journal-title":"Pflugers Arch"},{"issue":"7203","key":"21_CR20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature07034","volume":"454","author":"ME Carlson","year":"2008","unstructured":"Carlson ME, Hsu M, Conboy IM (2008) Imbalance between pSmad3 and Notch induces CDK inhibitors is old muscle stem cells. Nature 454(7203):528\u2013532","journal-title":"Nature"},{"issue":"1","key":"21_CR21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/rej.2007.0588","volume":"11","author":"B L\u00e9ger","year":"2008","unstructured":"L\u00e9ger B, Derave W, De Bock K, Hespel P, Russell AP (2008) Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 11(1):163\u2013175B","journal-title":"Rejuvenation Res"},{"issue":"6","key":"21_CR22","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1096\/fj.11-198663","volume":"26","author":"BR McKay","year":"2012","unstructured":"McKay BR, Ogborn DI, Bellamy LM, Tarnopolsky MA, Parise G (2012) Myostatin is associated with age-related human muscle stem cell dysfunction. FASEB J 26(6):2509\u20132521","journal-title":"FASEB J"},{"issue":"9","key":"21_CR23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/gerona\/glp068","volume":"64","author":"NK Lebrasseur","year":"2009","unstructured":"Lebrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA (2009) Myostatin inhibition enhances the effects on performance and metabolic outcomes in aged mice. J Gerontol: Ser A 64(9):940\u2013948","journal-title":"J Gerontol: Ser A"},{"issue":"11","key":"21_CR24","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1096\/fj.10-159608","volume":"24","author":"KT Murphy","year":"2010","unstructured":"Murphy KT, Koopman R, Naim T, L\u00e9ger B, Trieu J, Ibebunjo C, Lynch GS (2010) Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J 24(11):4433\u20134442","journal-title":"FASEB J"},{"issue":"3","key":"21_CR25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.nbd.2006.05.009","volume":"23","author":"EL Holzbaur","year":"2006","unstructured":"Holzbaur EL, Howland DS, Weber N, Wallace K, She Y, Kwak S, Tchistiakova LA, Murphy E, Hinson J, Karim R, Tan XY, Kelley P, McGill KC, Williams G, Hobbs C, Doherty P, Zaleska MM, Pangalos MN, Walsh FS (2006) Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis 23(3):697\u2013707","journal-title":"Neurobiol Dis"},{"issue":"5","key":"21_CR26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.2353\/ajpath.2010.090932","volume":"176","author":"KT Murphy","year":"2010","unstructured":"Murphy KT, Ryall JG, Snell SM, Nair L, Koopman R, Krasney PA, Ibebunjo C, Holden KS, Loria PM, Salatto CT, Lynch GS (2010) Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol 176(5):2425\u20132434","journal-title":"Am J Pathol"},{"issue":"3","key":"21_CR27","first-page":"R716","volume":"301","author":"KT Murphy","year":"2011","unstructured":"Murphy KT, Chee A, Gleeson BG, Naim T, Swiderski K, Koopman R, Lynch GS (2011) Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Phys Regul Integr Comp Phys 301(3):R716\u2013R726","journal-title":"Am J Phys Regul Integr Comp Phys"},{"issue":"6914","key":"21_CR28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, Krag TOB, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420(6914):418\u2013421","journal-title":"Nature"},{"issue":"6","key":"21_CR29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1096\/fj.04-2796com","volume":"19","author":"S Bogdanovich","year":"2005","unstructured":"Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS (2005) Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19(6):543\u2013549","journal-title":"FASEB J"},{"issue":"5","key":"21_CR30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","volume":"63","author":"KR Wagner","year":"2008","unstructured":"Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR (2008) A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63(5):561\u2013571","journal-title":"Ann Neurol"},{"issue":"3","key":"21_CR31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1152\/japplphysiol.00866.2009","volume":"109","author":"SM Cadena","year":"2010","unstructured":"Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL (2010) Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 109(3):635\u2013642","journal-title":"J Appl Physiol"},{"issue":"4","key":"21_CR32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM (2017) Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55(4):458\u2013464","journal-title":"Muscle Nerve"},{"key":"21_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jcph.1015","volume":"58","author":"I Bhattacharya","year":"2017","unstructured":"Bhattacharya I, Manukyan Z, Chan P, Heatherington A, Harnisch L (2017) Application of quantitative pharmacology approaches in bridging pharmacokinetics and pharmacodynamics of domagrozumab from adult healthy subjects to pediatric patients with Duchenne muscular disease. J Clin Pharmacol 58:314. https:\/\/doi.org\/10.1002\/jcph.1015","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"21_CR34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1096\/fj.14-257543","volume":"29","author":"KE O'Connell","year":"2015","unstructured":"O'Connell KE, Guo W, Serra C, Beck M, Wachtman L, Hoggatt A, Xia D, Pearson C, Knight H, O'Connell M, Miller AD, Westmoreland SV, Bhasin S (2015) The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques. FASEB J 29(4):1165\u20131175","journal-title":"FASEB J"},{"issue":"3","key":"21_CR35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncpendmet0120","volume":"2","author":"S Bhasin","year":"2006","unstructured":"Bhasin S, Calof O, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for physical dysfunction in chronic illness and ageing. Nat Clin Pract Endocrinol Metab 2(3):146\u2013159","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"3","key":"21_CR36","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1152\/ajpendo.00362.2001","volume":"282","author":"AA Ferrando","year":"2002","unstructured":"Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ (2002) Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol-Endocrinol Metab 282(3):E601\u2013E607","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"5","key":"21_CR37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1532-5415.2000.tb05002.x","volume":"48","author":"V Bakhshi","year":"2000","unstructured":"Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T (2000) Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc 48(5):550\u2013553","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"21_CR38","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1210\/jc.2006-0357","volume":"91","author":"I Sinha-Hikim","year":"2006","unstructured":"Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S (2006) Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metabol 91(8):3024\u20133033","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"21_CR39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","volume":"363","author":"S Basaria","year":"2010","unstructured":"Basaria S, Coviello AD, Travinson TG (2010) Adverse events associated with testosterone administratrion. N Engl J Med 363(2):109\u2013122","journal-title":"N Engl J Med"},{"issue":"4","key":"21_CR40","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1210\/jc.2002-021231","volume":"88","author":"TW Storer","year":"2003","unstructured":"Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S (2003) Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metabol 88(4):1478\u20131485","journal-title":"J Clin Endocrinol Metabol"},{"issue":"10","key":"21_CR41","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/gerona\/glr100","volume":"66","author":"TG Travison","year":"2011","unstructured":"Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, Choong K, Lakshman K, Mazer NA, Coviello AD, Knapp PE, Ulloor J, Zhang A, Brooks B, Nguyen AH, Eder R, LeBrasseur N, Elmi A, Appleman E, Hede-Brierley L, Bhasin G, Bhatia A, Lazzari A, Davis S, Ni P, Collins L, Bhasin S (2011) Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol: Ser A 66(10):1090\u20131099","journal-title":"J Gerontol: Ser A"},{"issue":"1","key":"21_CR42","first-page":"39","volume":"299","author":"MH Emmelot-Vonk","year":"2008","unstructured":"Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT (2008) Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 299(1):39\u201352","journal-title":"JAMA"},{"issue":"2","key":"21_CR43","first-page":"583","volume":"102","author":"TW Storer","year":"2017","unstructured":"Storer TW, Basaria S, Traustadottir T, Harman SM, Pencina K, Li Z, Travison TG, Miciek R, Tsitouras P, Hally K, Huang G, Bhasin S (2017) Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J Clin Endocrinol Metab 102(2):583\u2013593","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"21_CR44","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1152\/ajpendo.00362.2001","volume":"282","author":"AA Ferrando","year":"2002","unstructured":"Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ (2002) Testosterone administration to older men improves muscle function: molecular and physiologyical mechanisms. Am J Physiol-Endocrinol Metab 282(3):E601\u2013E607","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"3","key":"21_CR45","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1210\/en.2008-0858","volume":"150","author":"R Singh","year":"2009","unstructured":"Singh R, Bhasin S, Braga M (2009) Regulation of myogenic differentiation by androgens: cross talk between androgen receptor\/beta catenin and follistatin\/transforming growth factor-beta signaling pathways. Endocrinology 150(3):1259\u20131268","journal-title":"Endocrinology"},{"issue":"1","key":"21_CR46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bbrc.2007.07.023","volume":"361","author":"L Mendler","year":"2007","unstructured":"Mendler L, Baka Z, Kov\u00e1cs-Simon A, Dux L (2007) Androgens negatively regulate myostatin expression in an androgen-dependent skeletal muscle. Biochem Biophys Res Commun 361(1):237\u2013242","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"21_CR47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00223-015-0022-5","volume":"98","author":"JE Morley","year":"2016","unstructured":"Morley JE (2016) Pharmacologic options for the treatment of sarcopenia. Calcif Tissue Int 98(4):319\u2013333","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"21_CR48","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1021\/jm900280m","volume":"52","author":"ML Mohler","year":"2009","unstructured":"Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD (2009) Nonsteroidal selective androgen receptor modulatos (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeuticc benefit. J Med Chem 52(12):3598\u20133617","journal-title":"J Med Chem"},{"issue":"1","key":"21_CR49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/jpet.105.088344","volume":"315","author":"J Kim","year":"2005","unstructured":"Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT (2005) The Para substituent of S-3-(phenoxyl)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-prop ionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther 315(1):230\u2013239","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"21_CR50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","volume":"2","author":"JT Dalton","year":"2011","unstructured":"Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2(3):153\u2013161","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"21_CR51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","volume":"14","author":"AS Dobs","year":"2013","unstructured":"Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS (2013) Effects of enobosarm on muscle wasting and physical function in patients with dancer: a double-blind, randomized controlled phase 2 trial. Lancet Oncol 14(4):335\u2013345","journal-title":"Lancet Oncol"},{"issue":"1","key":"21_CR52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/gerona\/gls078","volume":"68","author":"S Basario","year":"2013","unstructured":"Basario S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S (2013) The safety, pharmacyokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator in healthy young men. J Gerontol: Ser A 68(1):87\u201395","journal-title":"J Gerontol: Ser A"},{"issue":"6","key":"21_CR53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","volume":"18","author":"J Crawford","year":"2016","unstructured":"Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hankock ML, Dalton JT (2016) Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials). Curr Oncol Rep 18(6):37","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"21_CR54","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1152\/physrev.00012.2004","volume":"85","author":"M Kojima","year":"2004","unstructured":"Kojima M, Kangawa K (2004) Ghrelin: structure and function. Physiol Rev 85(2):495\u2013522","journal-title":"Physiol Rev"},{"issue":"1","key":"21_CR55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1172\/JCI200421134","volume":"114","author":"VD Dixit","year":"2004","unstructured":"Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW Jr, Taub DD (2004) Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114(1):57\u201366","journal-title":"J Clin Invest"},{"issue":"2","key":"21_CR56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13539-010-0011-5","volume":"1","author":"T Akamizu","year":"2010","unstructured":"Akamizu T, Kangawa K (2010) Ghrelin for cachexia. J Cachexia Sarcopenia Muscle 1(2):169\u2013176","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"24","key":"21_CR57","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1161\/01.CIR.0000149746.62908.BB","volume":"110","author":"N Nagaya","year":"2004","unstructured":"Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110(24):3674\u20133679","journal-title":"Circulation"},{"issue":"4","key":"21_CR58","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1532-5415.2004.52156.x","volume":"52","author":"MA Bach","year":"2004","unstructured":"Bach MA, Rockwood K, Zetterberg C, Thamsborg G, H\u00e9bert R, Devogelaer JP, Christiansen JS, Rizzoli R, Ochsner JL, Beisaw N, Gluck O, Yu L, Schwab T, Farrington J, Taylor AM, Ng J, Fuh V, MK 0677 Hip Fracture Study Group (2004) The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 52(4):516\u2013523","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"21_CR59","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mce.2011.02.010","volume":"340","author":"R Nass","year":"2011","unstructured":"Nass R, Gaylinn BD, Thorner MO (2011) The ghrelin axis in disease: potential therapeutic indications. Mol Cell Endocrinol 340(1):106\u2013110","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"21_CR60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","volume":"5","author":"C Pietra","year":"2014","unstructured":"Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R (2014) Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle 5(4):329\u2013337","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"21_CR61","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00520-016-3560-0","volume":"25","author":"Y Bai","year":"2017","unstructured":"Bai Y, Hu Y, Zhao YYX, Xu J, Hua Z, Zhao Z (2017) Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support Care Cancer 25(5):1651\u20131659","journal-title":"Support Care Cancer"},{"issue":"7","key":"21_CR62","first-page":"2223","volume":"83","author":"DM Tham","year":"1998","unstructured":"Tham DM, Gardner CD, Haskell WL (1998) Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metabol 83(7):2223\u20132235","journal-title":"J Clin Endocrinol Metabol"},{"key":"21_CR63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsbmb.2015.09.002","volume":"154","author":"K Beekmann","year":"2015","unstructured":"Beekmann K, de Haan LH, Actis-Goretta L, Houtman R, van Bladeren PJ, Rietjens IM (2015) The effect of glucuronidation on isoflavone induced estrogen receptor (ER) \u03b1 and ER\u03b2 mediated coregulator interactions. J Steroid Biochem Mol Biol 154:245\u2013253","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"21_CR64","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/mnfr.201500240","volume":"59","author":"A Kurrat","year":"2015","unstructured":"Kurrat A, Blei T, Kluxen FM, Mueller DR, Piechotta M, Soukup ST, Kulling SE, Diel P (2015) Lifelong exposure to dietary isoflavones reduces risk of obesity in ovariectomized Wistar rats. Mol Nutr Food Res 59(12):2407\u20132418","journal-title":"Mol Nutr Food Res"},{"issue":"6","key":"21_CR65","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3945\/jn.115.226316","volume":"146","author":"S Aoyama","year":"2016","unstructured":"Aoyama S, Jia H, Nakazawa K, Yamamura J, Saito K, Kato H (2016) Dietary genistein prevents denervation-induced muscle atrophy in male rodents via effects on estrogen receptor-\u03b1. J Nutr 146(6):1147\u20131154","journal-title":"J Nutr"},{"key":"21_CR66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jnutbio.2017.07.017","volume":"49","author":"M Ogawa","year":"2017","unstructured":"Ogawa M, Kitano T, Kawata N, Sugihira T, Kitakaze T, Harada N, Yamaji R (2017) Daidzein down-regulates ubiquitin-specific protease 19 expression through estrogen receptor \u03b2 and increases skeletal muscle mass in young female mice. J Nutr Biochem 49:63\u201370","journal-title":"J Nutr Biochem"},{"issue":"25","key":"21_CR67","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1093\/hmg\/ddv439","volume":"24","author":"A Henriques","year":"2015","unstructured":"Henriques A, Croixmarie V, Priestman DA, Rosenbohm A, Dirrig-Grosch S, D'Ambra E, Huebecker M, Hussain G, Boursier-Neyret C, Echaniz-Laguna A, Ludolph AC, Platt FM, Walther B, Spedding M, Loeffler JP, Gonzalez De Aguilar JL (2015) Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet 24(25):7390\u20137405","journal-title":"Hum Mol Genet"},{"key":"21_CR68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.exger.2014.11.019","volume":"61","author":"BT Wall","year":"2015","unstructured":"Wall BT, Dirks ML, Snijders T, Stephens FB, Senden JM, Verscheijden ML, van Loon LJ (2015) Short-term muscle disuse atrophy is not associated with increased intramuscular lipid deposition or a decline in the maximal activity of key mitochondrial enzymes in young and older males. Exp Gerontol 61:76\u201383","journal-title":"Exp Gerontol"},{"key":"21_CR69","volume":"2013","author":"T Abe","year":"2013","unstructured":"Abe T, Kohno S, Yama T, Ochi A, Suto T, Hirasaka K, Ohno A, Teshima-Kondo S, Okumura Y, Oarada M, Choi I, Mukai R, Terao J, Nikawa T (2013) Soy glycinin contains a functional inhibitory sequence against muscle-atrophy-associated ubiquitin ligase Cbl-b. Int J Endocrinol 2013:907565","journal-title":"Int J Endocrinol"},{"issue":"6","key":"21_CR70","doi-asserted-by":"crossref","first-page":"C1490","DOI":"10.1152\/ajpcell.00255.2010","volume":"300","author":"SM Senf","year":"2011","unstructured":"Senf SM, Sandesara PB, Reed SA, Judge AR (2011) p300 acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle. Am J Phys Cell Phys 300(6):C1490\u2013C1501","journal-title":"Am J Phys Cell Phys"},{"key":"21_CR71","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1242\/jcs.136390","volume":"127","author":"AW Beharry","year":"2014","unstructured":"Beharry AW, Sandesara PB, Roberts BM, Ferreira LF, Senf SM, Judge AR (2014) HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy. J Cell Sci 127 .(Pt 7:1441\u20131453","journal-title":"J Cell Sci"},{"issue":"5","key":"21_CR72","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1534-5807(04)00107-8","volume":"6","author":"S Iezzi","year":"2004","unstructured":"Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, Zhao P, Hoffman EP, Puri PL, Sartorelli V (2004) Deacetylase inhibitors increases muscle cell size by promoting myoblast recruitment and fusion through induction of folliestatin. Dev Cell 6(5):673\u2013684","journal-title":"Dev Cell"},{"issue":"45","key":"21_CR73","doi-asserted-by":"crossref","first-page":"16977","DOI":"10.1073\/pnas.0601565103","volume":"103","author":"H Tang","year":"2006","unstructured":"Tang H, Goldman D (2006) Activity-dependent gene regulation in skeletal muscle is mediated by a histone deacetylase (HDAC)-Dach2-myogenin signal transduction cascade. Proc Natl Acad Sci U S A 103(45):16977\u201316982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"21_CR74","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1091\/mbc.e08-07-0759","volume":"20","author":"H Tang","year":"2009","unstructured":"Tang H, Macpherson P, Marvin M, Meadows E, Klein WH, Yang XJ, Goldman D (2009) A histone deacetylase 4\/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression. Mol Biol Cell 20(4):1120\u20131131","journal-title":"Mol Biol Cell"},{"issue":"20","key":"21_CR75","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1093\/hmg\/dds286","volume":"21","author":"KV Bricceno","year":"2012","unstructured":"Bricceno KV, Sampognaro PJ, Van Meerbeke JP, Sumner CJ, Fischbeck KH, Burnett BG (2012) Histone deacetylase inhibition suppresses myogenin-dependent atrogne activation in spinal muscular atrophy mice. Hum Mol Genet 21(20):4448\u20134459","journal-title":"Hum Mol Genet"},{"issue":"3","key":"21_CR76","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"AM Avila","year":"2007","unstructured":"Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, Cizman Z, Di Prospero NA, Pellizzoni L, Fischbeck KH, Sumner CJ (2007) Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117(3):659\u2013671","journal-title":"J Clin Invest"},{"issue":"4","key":"21_CR77","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1152\/japplphysiol.01031.2014","volume":"119","author":"S Dupr\u00e9-Aucouturier","year":"2015","unstructured":"Dupr\u00e9-Aucouturier S, Castells J, Freyssenet D, Desplanches D (2015) Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy. J Appl Physiol 119(4):342\u2013351","journal-title":"J Appl Physiol"},{"issue":"5","key":"21_CR78","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2174\/156800909789057015","volume":"9","author":"A Bonetto","year":"2009","unstructured":"Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, Costelli P (2009) Deacetylase inhibitors modulate the myostatin\/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 9(5):608\u2013616","journal-title":"Curr Cancer Drug Targets"},{"issue":"1\u20133","key":"21_CR79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejphar.2009.01.005","volume":"628","author":"ZH Wang","year":"2009","unstructured":"Wang ZH, Hsu CC, Huang CN, Yin MC (2009) Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice. Eur J Pharmacol 628(1\u20133):255\u2013260","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"21_CR80","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.cmet.2011.03.020","volume":"13","author":"SD Kunkel","year":"2011","unstructured":"Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, Alipour F, Shields RK, Adams CM (2011) mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 13(6):627\u2013638","journal-title":"Cell Metab"},{"issue":"6","key":"21_CR81","doi-asserted-by":"crossref","first-page":"E760","DOI":"10.1152\/ajpendo.00302.2013","volume":"305","author":"R Ogasawara","year":"2013","unstructured":"Ogasawara R, Sato K, Higashida K, Nakazato K, Fujita S (2013) Ursolic acid stimulates mTORC1 signaling after resistance exercise in rat skeletal muscle. Am J Physiol-Endocrinol Metab 305(6):E760\u2013E765","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"6","key":"21_CR82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039332","volume":"7","author":"SD Kunkel","year":"2012","unstructured":"Kunkel SD, Elmore CJ, Bongers KS (2012) Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One 7(6):e39332","journal-title":"PLoS One"},{"issue":"11","key":"21_CR83","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI118698","volume":"97","author":"M Brink","year":"1996","unstructured":"Brink M, Wellen J, Delafontaine P (1996) Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 97(11):2509\u20132516","journal-title":"J Clin Invest"},{"issue":"4","key":"21_CR84","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1210\/endo.142.4.8082","volume":"142","author":"M Brink","year":"2001","unstructured":"Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P (2001) Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 142(4):1489\u20131496","journal-title":"Endocrinology"},{"issue":"2","key":"21_CR85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI22324","volume":"115","author":"YH Song","year":"2005","unstructured":"Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P (2005) Muscle-specific expression of IGF-I blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115(2):451\u2013458","journal-title":"J Clin Invest"},{"issue":"5","key":"21_CR86","first-page":"H1565","volume":"298","author":"T Yoshida","year":"2010","unstructured":"Yoshida T, Semprun-Prieto L, Wainford RD, Delafontaine P (2010) IGF-I prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase. Am J Phys Heart Circ Phys 298(5):H1565\u2013H1570","journal-title":"Am J Phys Heart Circ Phys"},{"issue":"23","key":"21_CR87","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1161\/01.CIR.99.23.3043","volume":"99","author":"JE Fabre","year":"1999","unstructured":"Fabre JE, Rivard A, Magner M, Silver M, Isner JM (1999) Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99(23):3043\u20133049","journal-title":"Circulation"},{"issue":"10","key":"21_CR88","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.amjcard.2005.11.089","volume":"97","author":"M Maggio","year":"2006","unstructured":"Maggio M, Ceda GP, Lauretani F, Pahor M, Bandinelli S, Najjar SS, Ling SM, Basaria S, Ruggiero C, Valenti G, Ferrucci L (2006) Relation of angiotensin converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects > 65 years of age (the InCHIANTI study). Am J Cardiol 97(10):1525\u20131529","journal-title":"Am J Cardiol"},{"issue":"9363","key":"21_CR89","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","volume":"361","author":"SD Anker","year":"2003","unstructured":"Anker SD, Negassa A, Coats AJS (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensain-converting-enzyme inhibitors: an observational study. Lancet 361(9363):1077\u20131083","journal-title":"Lancet"},{"issue":"3","key":"21_CR90","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/phrs.1998.0288","volume":"37","author":"S Masson","year":"1998","unstructured":"Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, Torri M, Anesini A, Salio M, Pasotti E, Agnello D, Santoro L, Catania A, Ghezzi P, Moccetti T, Maggioni AP (1998) Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 37(3):213\u2013217","journal-title":"Pharmacol Res"},{"issue":"6","key":"21_CR91","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1203\/01.pdr.0000246100.14061.bc","volume":"60","author":"AC Simoes e Silva","year":"2006","unstructured":"Simoes e Silva AC, Diniz JS, Pereira RM, Pinheiro SV, Santos RA (2006) Circulating renin angiotensin in childhood chronic renal failure: marked increase of angiotensin-(1-7) in end-stage renal disease. Pediatr Res 60(6):734\u2013739","journal-title":"Pediatr Res"},{"issue":"9310","key":"21_CR92","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(02)08024-8","volume":"359","author":"G Onder","year":"2002","unstructured":"Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M (2002) Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 359(9310):926\u2013930","journal-title":"Lancet"},{"issue":"8","key":"21_CR93","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1503\/cmaj.061339","volume":"177","author":"D Sumukadas","year":"2007","unstructured":"Sumukadas D, Witham MD, Struthers AD, McMurdo ME (2007) Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 177(8):867\u2013874","journal-title":"CMAJ"},{"key":"21_CR94","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/eurheartj\/14.suppl_C.18","volume":"14","author":"L D\u00f6ssegger","year":"1993","unstructured":"D\u00f6ssegger L, Aldor E, Baird MG Braun S, Cleland JG, Donaldson R, Jansen LJ, Joy MD, Marin-Neto JA, Nogueira E (1993) Influence of angiotensin converting enzyme-inhibition on exercise performance and clinical symptoms in chronic heart-failure-a multicenter, double-blind, placebo-controlled trial. Eur Heart J 14:18\u201323","journal-title":"Eur Heart J"},{"issue":"11","key":"21_CR95","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/j.1532-5415.2005.53568.x","volume":"53","author":"GD Schellenbaum","year":"2005","unstructured":"Schellenbaum GD, Smith NL, Heckbert SR Lumley T, Rea TD, Furberg CD, Lyles MF, Psaty BM (2005) Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc 53(11):1996\u20132000","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"21_CR96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1470320309105338","volume":"10","author":"D Bunout","year":"2009","unstructured":"Bunout D, Barrera G, De L, Maza MP Leiva L, Backhouse C, Hirsch S (2009) Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial. J Renin-Angiotensin-Aldosterone Syst 10(2):77\u201384","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"1","key":"21_CR97","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13063-017-2390-9","volume":"19","author":"MM Band","year":"2018","unstructured":"Band MM, Sumukadas D, Struthers AD, Avenell A, Donnan PT, Kemp PR, Smith KT, Hume CL, Hapca A, Witham MD (2018) Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomized controlled trial. Trials 19(1):6","journal-title":"Trials"},{"issue":"19","key":"21_CR98","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","volume":"62","author":"SV Arnold","year":"2013","unstructured":"Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, Dodson JA, Chan PS (2013) Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol 62(19):1791\u20131801","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"21_CR99","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cjca.2014.02.016","volume":"30","author":"JM Castellano","year":"2014","unstructured":"Castellano JM, Sanz G, Fuster V (2014) Evolution of the polypill concept and ongoing clinical trials. Can J Cardiol 30(5):520\u2013526","journal-title":"Can J Cardiol"},{"issue":"1","key":"21_CR100","first-page":"R24","volume":"305","author":"CC Carroll","year":"2013","unstructured":"Carroll CC, O\u2019Connor DT, Steinmeyer R, Del Mundo JD, McMullan DR, Whitt JA, Ramos JE, Gonzales RJ (2013) The influence of acute resistance exercise on cyclooxygenase-1 and -2 activity and protein levels in human skeletal muscle. Am J Phys Regul Integr Comp Phys 305(1):R24\u2013R30","journal-title":"Am J Phys Regul Integr Comp Phys"},{"issue":"3","key":"21_CR101","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.103.063099","volume":"308","author":"TW Davis","year":"2004","unstructured":"Davis TW, Zweifel BS, O\u2019Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL (2004) Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 308(3):929\u2013934","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"21_CR102","first-page":"223","volume":"4","author":"AJ Baumgarten","year":"2007","unstructured":"Baumgarten AJ, Fiebig HH, Burger AM (2007) Molecular analysis of xenograft models of human cancer cachexia-possibilities for therapeutic intervention. Cancer Genomics Proteomics 4(3):223\u2013231","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"21_CR103","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","volume":"88","author":"G Mantovani","year":"2010","unstructured":"Mantovani G, Macci\u00f3 A, Madeddu C, Serpe R, Antoni G, Massa E, Dess\u00ec M, Panzone F (2010) Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med 88(1):85\u201392","journal-title":"J Mol Med"},{"issue":"1","key":"21_CR104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hed.20662","volume":"30","author":"V Lai","year":"2008","unstructured":"Lai V, George J, Richery L, Kim HJ, Cannon T, Shores C, Couch M (2008) Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 30(1):67\u201374","journal-title":"Head Neck"},{"issue":"5","key":"21_CR105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1476-5381.2010.00957.x","volume":"161","author":"FI Romero","year":"2010","unstructured":"Romero FI, Mart\u00ednez-Calatrava MJ, S\u00e1nchez-Pernaute O, Gualillo O, Largo R, Herrero-Beaumont G (2010) Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. Br J Pharmacol 161(5):1012\u20131022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"21_CR106","first-page":"L184","volume":"299","author":"GS Roh","year":"2010","unstructured":"Roh GS, Yi CO, Cho YJ, Jeon BT, Nizamudtinova IT, Kim HJ, Kim JH, Oh YM, Huh JW, Lee JH, Hwang YS, Lee SD, Lee JD (2010) Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema. Am J Phys Lung Cell Mol Phys 299(2):L184\u2013L191","journal-title":"Am J Phys Lung Cell Mol Phys"},{"issue":"1","key":"21_CR107","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/jtd.2017.01.23","volume":"9","author":"Z Shi","year":"2017","unstructured":"Shi Z, Chen Y, Pei Y, Long Y, Liu C, Cao J, Chen P (2017) The role of cyclooxygenase-2 in the protection against apoptosis in vascular endothelial cells induced by cigarette smoking. J Thorac Dis 9(1):30\u201341","journal-title":"J Thorac Dis"},{"issue":"1","key":"21_CR108","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.20903","volume":"60","author":"ME Cudkowicz","year":"2006","unstructured":"Cudkowicz ME, Shefner JM, Schoenfeld DA (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60(1):22\u201331","journal-title":"Ann Neurol"},{"issue":"4","key":"21_CR109","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/17482960802195632","volume":"9","author":"PH Gordon","year":"2008","unstructured":"Gordon PH, Cheung YK, Levin B Andrews H, Doorish C, Macarthur RB, Montes J, Bednarz K, Florence J, Rowin J, Boylan K, Mozaffar T, Tandan R, Mitsumoto H, Kelvin EA, Chapin J, Bedlack R, Rivner M, McCluskey LF, Pestronk A, Graves M, Sorenson EJ, Barohn RJ, Belsh JM, Lou JS, Levine T, Saperstein D, Miller RG, Scelsa SN, Combination Drug Selection Trial Study Group (2008) A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 9(4):212\u2013222","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"21_CR110","first-page":"649","volume":"63","author":"AI Martin","year":"2012","unstructured":"Martin AI, Nieto-Bona MP, Castillero E, Fernandez-Galaz C, Lopez-Menduina M, Gomez-Sanmiguel AB, Gomez-Moreira C, Villanua MA, Lopez-Calderon A (2012) Effect of cyclooxygenase-2 inhibition by meloxicam, on atrogin-1 and myogenic regulatory factors in skeletal muscle of rats injected with endotoxin. J Physiol Pharmacol 63(6):649\u2013659","journal-title":"J Physiol Pharmacol"},{"issue":"1","key":"21_CR111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1097-0215(20000701)87:1<95::AID-IJC14>3.0.CO;2-D","volume":"87","author":"HJ Hussey","year":"2000","unstructured":"Hussey HJ, Tisdale MJ (2000) Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumor growth and cachexia in a murine model. Int J Cancer 87(1):95\u2013100","journal-title":"Int J Cancer"},{"issue":"6","key":"21_CR112","doi-asserted-by":"crossref","first-page":"E1656","DOI":"10.1152\/ajpendo.00502.2006","volume":"292","author":"M Granado","year":"2007","unstructured":"Granado M, Martin AI, Villan\u00faa MA, L\u00f3pez-Calder\u00f3n A (2007) Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation. Am J Physiol-Endocrinol Metab 292(6):E1656\u2013E1665","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"21_CR113","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fendo.2014.00061","volume":"5","author":"L Zeng","year":"2014","unstructured":"Zeng L, Holly JM, Perks CM (2014) Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cell. Front Endocrinol 5:61","journal-title":"Front Endocrinol"},{"key":"21_CR114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.redox.2013.12.022","volume":"2","author":"HS Kim","year":"2014","unstructured":"Kim HS, Quon MJ, Kim JA (2014) New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol 2:187\u2013195","journal-title":"Redox Biol"},{"key":"21_CR115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.exger.2013.11.011","volume":"50","author":"SE Alway","year":"2014","unstructured":"Alway SE, Bennett BT, Wilson JC, Edens NK, Pereira SL (2014) Epigallocatechin-3-gallate improves plantaris muscle recovery after disuse in aged rats. Exp Gerontol 50:82\u201394","journal-title":"Exp Gerontol"},{"issue":"6","key":"21_CR116","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00418-012-0926-3","volume":"137","author":"Y Nakae","year":"2012","unstructured":"Nakae Y, Dorchies OM, Stoward PJ, Zimmermann BF, Ritter C, Ruegg UT (2012) Quantitative evaluation of the beneficial effects in the mdx mouse of epugallocatechin gallate, an antioxidant polyphenol from green tea. Histochem Cell Biol 137(6):811\u2013827","journal-title":"Histochem Cell Biol"},{"issue":"3","key":"21_CR117","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clnu.2009.10.001","volume":"29","author":"NP Evans","year":"2010","unstructured":"Evans NP, Call JA, Bassaganya-Riera J, Robertson JL, Grange RW (2010) Green tea extract decreases muscle pathology and NF-kB immunostaining in regenerating muscle fibers of mdx mice. Clin Nutr 29(3):391\u2013398","journal-title":"Clin Nutr"},{"key":"21_CR118","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.exger.2017.02.075","volume":"92","author":"H Takahashi","year":"2017","unstructured":"Takahashi H, Suzuki Y, Mohamed JS, Gotoh T, Pereira SL, Always SE (2017) Epigallocatechin-3-gallate increases autophagy signaling in resting and unloaded plantaris muscles but selectively suppresses autophagy protein abundance in reloaded muscles of aged rats. Exp Gerontol 92:56\u201366","journal-title":"Exp Gerontol"},{"issue":"12","key":"21_CR119","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jnutbio.2015.07.023","volume":"26","author":"RJ Wimmer","year":"2015","unstructured":"Wimmer RJ, Russell SJ, Schneider MF (2015) Green tea component EGCG, insulin and IGF-I promote nuclear efflux of atrophy-associated transcription factor Foxo1 in skeletal muscle fibers. J Nutr Biochem 26(12):1559\u20131567","journal-title":"J Nutr Biochem"},{"issue":"2","key":"21_CR120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1139\/apnm-2015-0372","volume":"41","author":"BD Pence","year":"2016","unstructured":"Pence BD, Gibbons TE, Bhattacharya TK Mach H, Ossyra JM, Petr G, Martin SA, Wang L, Rubakhin SS, Sweedler JV, McCusker RH, Kelley KW, Rhodes JS, Johnson RW, Woods JA (2016) Effects of exercise and dietary epigallocatechin gallate and \u03b2-alanine on skeletal muscle in aged mice. Appl Physiol Nutr Metab 41(2):181\u2013190","journal-title":"Appl Physiol Nutr Metab"}],"container-title":["Advances in Experimental Medicine and Biology","Muscle Atrophy"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-13-1435-3_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T17:45:58Z","timestamp":1572457558000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-13-1435-3_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9789811314346","9789811314353"],"references-count":120,"URL":"https:\/\/doi.org\/10.1007\/978-981-13-1435-3_21","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}